News & Publications

News & Publications

HighField Press Releases

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates

HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions

HighField in the News

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Clinical Trials Arena: HighField Bio initiates its glioma trial with first patient dosing

Biospace: HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma

Biospace: HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Publications

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment

Scientific References

Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment

Comparative properties and methods of preparation of lipid vesicles (liposomes)

Gluagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

Upcoming HighField Events

The current query has no posts. Please make sure you have published items matching your query.